Scarica l'app Stockscreener
0.585
66.48%
0.2336
Dopo l'orario di chiusura:
.54
-0.045
-7.69%
Precedente Chiudi:
$0.3514
Aprire:
$0.565
Volume 24 ore:
14.90M
Relative Volume:
22.32
Capitalizzazione di mercato:
$45.46M
Reddito:
$8.23M
Utile/perdita netta:
$-32.49M
Rapporto P/E:
-1.1038
EPS:
-0.53
Flusso di cassa netto:
$-19.91M
1 W Prestazione:
-30.02%
1M Prestazione:
-28.69%
6M Prestazione:
-37.31%
1 anno Prestazione:
-49.13%
Intervallo 1D:
$0.55
$0.60
Intervallo di 1 settimana:
$0.292
$0.8383
Portata 52W:
$0.292
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Nome
Clearside Biomedical Inc
Settore
Industria
Telefono
678-270-3631
Indirizzo
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Confronta CLSD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.585 | 27.31M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2025-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-18 | Downgrade | Stifel | Buy → Hold |
| 2024-08-21 | Iniziato | Chardan Capital Markets | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2021-12-15 | Ripresa | Wedbush | Outperform |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-13 | Iniziato | ROTH Capital | Buy |
| 2019-08-09 | Downgrade | Needham | Buy → Hold |
| 2018-11-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2018-11-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Downgrade | Stifel | Buy → Hold |
| 2018-03-06 | Reiterato | Needham | Buy |
| 2017-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-02-24 | Iniziato | JP Morgan | Overweight |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-10-24 | Reiterato | Stifel | Buy |
Mostra tutto
Clearside Biomedical Inc Borsa (CLSD) Ultime notizie
What analysts say about Clearside Biomedical Inc. stockPhenomenal wealth increase - Autocar Professional
Is Clearside Biomedical Inc. a good long term investmentExceptional portfolio growth - Autocar Professional
Clearside Biomedical stock soars after Health Canada approves XIPERE - Investing.com Australia
Clearside Biomedical stock soars after Health Canada approves XIPERE By Investing.com - Investing.com UK
Health Canada approves Clearside’s XIPERE for uveitic macular edema By Investing.com - Investing.com Nigeria
Clearside Biomedical Announces Approval of XIPERE® - GlobeNewswire
Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema - Stock Titan
Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Growth Investment Group - Newser
Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare
What drives Clearside Biomedical Inc. stock priceTremendous return on equity - jammulinksnews.com
Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World
Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com
Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat
Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World
What institutions are buying Clearside Biomedical Inc. stock nowFree Stock Trading Signals - beatles.ru
Clearside Biomedical Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
Published on: 2025-07-18 21:44:13 - Newser
Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Health Care Stocks Stumble As Sector Faces Fresh Setbacks - Finimize
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga
Published on: 2025-07-18 22:42:56 - jammulinksnews.com
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $0.84 to $3 - 富途牛牛
Clearside Biomedical downgraded to Neutral from Buy at Chardan - TipRanks
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
CLSD: Downgraded to Neutral by HC Wainwright & Co. | CLSD Stock News - GuruFocus
Why Clearside Biomedical Inc. stock is on top investor watchlistsHigh Return Stock Alerts - Newser
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral By Investing.com - Investing.com Canada
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral - Investing.com
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns By Investing.com - Investing.com Nigeria
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns - Investing.com Australia
Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties - TipRanks
Clearside Biomedical downgraded to Hold from Buy at Stifel - TipRanks
Clearside Biomedical Announces Plan to Explore Strategic - GlobeNewswire
Alpharetta biomedical company ‘exploring strategic alternatives’ as job cuts loom - The Business Journals
Clearside Biomedical shares dip after announcing exploration of strategic alternatives - MSN
Clearside Biomedical to explore strategic alternatives to advance SCS platform - TipRanks
Citizens JMP downgrades Clearside Biomedical stock rating as company pauses R&D - Investing.com Canada
Clearside Biomedical's Stock Plummets 25%: Strategic Overhaul or Value Opportunity? - AInvest
Needham downgrades Clearside Biomedical stock to Hold on funding challenges - Investing.com Canada
Clearside Biomedical (CLSD) Downgraded by Needham to Hold | CLSD Stock News - GuruFocus
Needham downgrades Clearside on ‘disappointing’ decision to explore options - TipRanks
Clearside Biomedical Inc Azioni (CLSD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):